Rituximab/CHOP Combo Effective in Low-Grade NHL

Oncology NEWS InternationalOncology NEWS International Vol 9 No 3
Volume 9
Issue 3

Among patients with low-grade non-Hodgkin’s lymphoma (NHL), combining CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy with rituximab (Rituxan) adds therapeutic benefit

NEW ORLEANS—Among patients with low-grade non-Hodgkin’s lymphoma (NHL), combining CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy with rituximab (Rituxan) adds therapeutic benefit without causing significant additional toxicity. Rituximab is a human/murine monoclonal antibody that targets the CD20 antigen on B cells.

“We already know that CHOP chemotherapy has activity in low-grade lymphomas, just as we know that rituximab has activity as well. What we didn’t know was whether we could safely and effectively combine these two, chemotherapy with immunotherapy,” said Myron S. Czuczman, MD, assistant professor of medicine and head of the lymphoma service, Roswell Park Cancer Institute, Buffalo, NY. Dr. Czuczman presented the study results at the 41st Annual Meeting of the American Society of Hematology.

The study included 40 patients with low-grade follicular NHL, 31 of whom were treatment naïve. Among the 21 male and 19 female participants (median age, 48 years), 83% had stage III or IV disease.

CHOP was administered at standard doses over 3 weeks for six cycles along with six infusions of rituximab (375 mg/m²/dose). Two doses of rituximab were given both at the beginning and end of therapy, as well as single doses before the third and fifth cycles of CHOP.

All of the 38 patients who actually received treatment responded, with investigators recording complete responses (CR) in 58% of patients and partial responses (PR) in 42%. Among the 35 patients who completed all therapy, the overall response rate was also 100% (63% CR, 37% PR).

The majority of adverse events were mostly grade 1 or 2, with 17% of overall adverse events reported as grade 3 or 4. They consisted primarily of hematologic or infectious toxicities felt to be associated with CHOP chemotherapy.

While cautioning that the current trial was not prospectively randomized, Dr. Czuczman pointed to some particularly encouraging findings. “We know from many other studies looking at CHOP chemotherapy that time to progression is usually within about 2 years. Among these patients who received CHOP plus rituximab, we are now going out to 47.2 months, and more than half of these patients are still in remission,” he said.

Dr. Czuczman noted that some critics might attribute the high success rate to the fact that 31 of the 40 patients were treatment naïve. “I would say that, perhaps, if these patients continue progression-free, maybe we should rethink the way we treat patients with follicular lymphoma,” he said.

He noted that “this is an incurable illness, and we want the best possible response. Instead of giving small amounts of drugs and allowing patients to develop chemotherapy-resistant cells, maybe we should be using our best arsenal up front, especially since we are not getting additional toxicity.”

In another ASH presentation based on the same study, Antonio J. Grillo-López, MD, chief medical officer, IDEC Pharmaceuticals Corporation, San Diego, noted that among the 38 responders, there was an initial rapid decline in mean SPD (sum of the products of the perpendicular diameters) of all measurable lesions, with a slower SPD decline continuing for 10 or more months. That phenomenon, he said, has been observed previously in rituximab monotherapy and in combination with CHOP.

Progressive decreases in tumor size can be seen for as long as 16 months, and responses can be achieved, he emphasized, as late as 10 months after treatment. “For the usual chemotherapy regimen, you would see a rapid drop in SPD and then a stabilization rather than a continued fall,” Dr. Grillo-López pointed out in an interview.

The important message, he said, “is that if you treat a patient with the antibody and achieve stable disease (asymptomatic with some tumor shrinkage), you need to resist the temptation to go right away to some salvage chemotherapy regimen, because some patients do become responders later on.”

Related Videos
Experts on multiple myeloma
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Experts on multiple myeloma
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
Experts on MM
Experts on colorectal cancer
Experts on MM
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Experts on multiple myeloma